TGen Drug Development (TD2) and Flagship Biosciences offer combined oncology and pathology services for pharmaceutical and biotech clients.
FLAGSTAFF, Ariz. — Jan. 26, 2011 — TGen Drug Development
(TD2) and Flagship Biosciences today announced a strategic alliance that should
help speed new drugs safely into human testing and quickly benefit cancer
patients.
Read more of – Arizona companies team up, providing quick development of cancer drugs